TWD
MLYS icon

True Wealth Design’s Mineralys Therapeutics MLYS Stock Holding History

True Wealth Design’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.05K Hold
76
– – ﹤0.01% 1683
2026
Q1 		$2.06K Hold
76
– – ﹤0.01% 1530
2025
Q4 		$2.76K Hold
76
– – ﹤0.01% 1329
2025
Q3 		$2.88K Hold
76
– – ﹤0.01% 1329
2025
Q2 		$1.03K Buy
+76
New +$1.1K ﹤0.01% 1450

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

True Wealth Design's MLYS Position: Q2 2026 in Review

True Wealth Design held its Mineralys Therapeutics (MLYS) position steady in Q2 2026 at 76 shares worth $2.05K. The position accounts for ﹤0.01% of the portfolio, ranked #1683.

True Wealth Design first reported a position in MLYS in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.88K in Q3 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • True Wealth Design held 76 shares of Mineralys Therapeutics worth $2.05K as of Q2 2026.
  • True Wealth Design left its Mineralys Therapeutics share count unchanged in Q2 2026.
  • Mineralys Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #1683 holding.
  • True Wealth Design first reported a position in Mineralys Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • True Wealth Design's Mineralys Therapeutics position peaked at $2.88K in Q3 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.